China · Delayed Price · Currency is CNY Sinocelltech Group Company Description
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China.
The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers.
It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease.
The company was founded in 2002 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
| Country | China |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,277 |
| CEO | Liangzhi Xie |
Contact Details
Address: No. 31, Kechuang 7th Street Beijing, 100176 China | |
| Phone | 86 10 5862 8288 |
| Website | sinocelltech.com |
Stock Details
| Ticker Symbol | 688520 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003ZL3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liangzhi Xie Ph.D. | Chairman of the Board and GM |
| Jie Ma | Accounting Supervisor and Financial Director |
| Dr. Yang Wang | Deputy GM and Director |
| Fanbin Pan | Head of Engineering Equipment Department |
| Li Ming Tang | Deputy GM, Secretary of the Board and Director |
| Yan Jing Zhang | Executive Director of Preclinical Research & Development Center |
| Chun Yun Sun | Executive Director of Preclinical Research & Development Center |
| Chun Xia Luo | Person in charge of Pilot and Production Workshop |